Opendata, web and dolomites

PROTOCOL

New processing technology for colistmethate sodium, leading to improved and cost-effective formulations for pharmaceutical and veterinary markets

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PROTOCOL project word cloud

Explore the words cloud of the PROTOCOL project. It provides you a very rough idea of what is the project "PROTOCOL" about.

markets    practical    thorough    sodium    validation    delivered    supply    life    drying    market    cidqo    freeze    returns    2012    actual    gram    pharmaceutical    cms    hereinafter    energetic    commercialized    final    expertise    financial    form    sterile    founded    instrument    multidrug    combination    active    finish    custom    business    treatment    resistant    lc    advantages    ultrafiltration    solutions    ms    innovation    price    evaporation    manufacturing    plan    minimize    industrial    perform    staff    coupled    agent    ingredients    feasibility    formulation    negative    chances    veterinary    bactericidal    antimicrobial    chemical    hplc    antibiotic    commercial    exploited    verify    medicine    pyrogenic    threatening    commercialization    effect    alternative    colistimethate    infections    economic    viability    opportunity    sme    pathogens    good    quality    maximize    nosocomial    limitations    relies    risks    aqueous    post    phd    scaling    outstanding   

Project "PROTOCOL" data sheet

The following table provides information about the project.

Coordinator
CIDQO 2012 SL 

Organization address
address: POLIGONO INDUSTRIAL CAN VERDALET CARRER D NAU 91
city: TORDERA
postcode: 8490
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.cidqo.com/Noticias/News/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
2. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CIDQO 2012 SL ES (TORDERA) coordinator 50˙000.00

Map

 Project objective

Colistimethate Sodium (CMS hereinafter) is a rapidly bactericidal antimicrobial agent with a significant post-antibiotic effect against multidrug resistant Gram-negative pathogens. CMS represents a reliable alternative for the treatment of life-threatening nosocomial infections but today the market supply of CMS relies on industrial processes based on freeze drying of CMS aqueous solutions. This represents outstanding energetic costs that directly affect the final price of CMS. CIDQO is an SME founded in 2012 and its PhD staff has a wide expertise and know-how on the development and scaling-up of chemical processes, as well as on custom manufacturing of active pharmaceutical ingredients. CIDQO aims to undertake an innovation project to solve the current limitations of CMS supply, through the industrial validation of a new processing technology based on the combination of ultrafiltration and evaporation coupled to HPLC/LC-MS. The key market opportunity of the new processing technology relies on its ability to deliver a non-pyrogenic and sterile CMS formulation to be commercialized on the Pharmaceutical and Veterinary medicine markets, which will represent several advantages in terms of price and quality compared with the current commercial form. The overall plan to reach the market needs to be defined in the short term since the innovation process is next to finish. Phase 1 of SME Instrument represents a good opportunity to get the financial support required to perform a thorough market study not only to minimize risks but also to set up a business plan for commercialization. The main objective is to perform a thorough feasibility study to verify the practical and economic viability in Pharmaceutical and Veterinary markets of the CMS form to be delivered by the new processing technology. The actual market chances that can be exploited to maximize the economic returns will be analyzed and a detailed business plan will be developed.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROTOCOL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PROTOCOL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.3.1.;H2020-EU.2.1.2.)

S3D (2015)

Feasibility study to determine the use of ITS technology to replace nuclear density meters in mining, dredging and other areas of hydraulic transport.

Read More  

INFINITE (2015)

INnovative laser machine For INdustrial engravIng and 3d TExturing

Read More  

MySpark (2016)

The Complete Solution for Fast and Cost-efficient Yeast Separation Process in Production of High Quality Sparkling Wine

Read More